文献速递胸部肿瘤

循环肿瘤DNA分析预测不可切除III期非小细胞肺癌短程巩固免疫治疗结局

Analysis of Circulating Tumor DNA Predicts Outcomes of Short-Course Consolidation Immunotherapy in Unresectable Stage III NSCLC.
PubMed 文献 · J Thorac Oncol · 2024-07-05

本研究在LUN 16-081二期试验中,对不可切除III期非小细胞肺癌患者放化疗后短程巩固免疫治疗期间的血浆ctDNA进行肿瘤知情MRD分析。结果显示,各时间点可检测到ctDNA均与更差的无进展生存显著相关,ctDNA水平升高者均在启动免疫治疗后12个月内进展,提示ctDNA MRD分析可能有助于个体化巩固免疫治疗时长。

要点

  • 放化疗后、免疫治疗C2D1前及治疗结束时检出ctDNA均预测更差无进展生存。
  • 免疫治疗1周期后ctDNA下降或不可检出者结局优于ctDNA升高者(24个月PFS 72% vs 0%,p<0.0001)。
  • C2D1时ctDNA升高者均在启动免疫治疗后12个月内出现疾病进展。

核心结论

  • 在6个月巩固免疫治疗前、中、后检出ctDNA与更差结局强烈相关,ctDNA MRD分析可能使巩固免疫治疗时长个体化。

研究设计与样本

  • 研究为二期试验Big Ten Cancer Research Consortium LUN 16-081的ctDNA分析,纳入不可切除局部晚期非小细胞肺癌放化疗后接受短程巩固免疫治疗的患者。
  • 血浆样本采集时点为放化疗完成后、免疫治疗第2周期第1天(C2D1,即治疗开始后1个月)前及最多6个月治疗结束时。
  • 采用深部测序癌症个体化分析进行肿瘤知情ctDNA MRD检测,各时间点ctDNA水平与临床结局进行相关性分析。

主要发现

  • 放化疗完成后检出ctDNA者24个月无进展生存为29%,未检出者为65%(p=0.0048)。
  • 免疫治疗C2D1前检出ctDNA者24个月无进展生存为0%,未检出者为72%(p<0.0001)。
  • 免疫治疗结束时检出ctDNA者24个月无进展生存为15%,未检出者为67%(p=0.0011)。
  • 免疫治疗1周期后ctDNA下降或不可检出者24个月无进展生存为72%,ctDNA升高者为0%(p<0.0001)。
  • C2D1时ctDNA升高的所有患者均在启动免疫治疗后12个月内出现疾病进展。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The current standard of care for patients with inoperable stage III non-small cell lung cancer includes chemoradiotherapy (CRT) followed by 1 year of checkpoint inhibitor (CPI) therapy. Nevertheless, the optimal duration of consolidation CPI remains unknown. Here, we characterized the relationship between circulating tumor DNA (ctDNA) minimal residual disease (MRD) and clinical outcomes of patients with unresectable locally advanced non-small cell lung cancer treated on a phase 2 trial of short-course consolidation immunotherapy after CRT, with the goal of testing whether ctDNA may be able to identify patients who do not require a full year of treatment. METHODS: Plasma samples for ctDNA analysis were collected from patients on the Big Ten Cancer Research Consortium LUN 16-081 trial after completion of CRT, before day 1 of cycle 2 (C2D1) of CPI (i.e., 1 mo after treatment start), and at the end of up to 6 months of treatment. Tumor-informed ctDNA MRD analysis was performed using cancer personalized profiling by deep sequencing. Levels of ctDNA at each time point were correlated with clinical outcomes. RESULTS: Detection of ctDNA predicted significantly inferior progression-free survival after completion of CRT (24-mo 29% versus 65%, p = 0.0048), before C2D1 of CPI (24-mo 0% versus 72%, p < 0.0001) and at the end of CPI (24-mo 15% versus 67%, p = 0.0011). In addition, patients with decreasing or undetectable ctDNA levels after 1 cycle of CPI had improved outcomes compared with patients with increasing ctDNA levels (24-mo progression-free survival 72% versus 0%, p < 0.0001). Progression of disease occurred within less than 12 months of starting CPI in all patients with increasing ctDNA levels at C2D1. CONCLUSIONS: Detection of ctDNA before, during, or after 6 months of consolidation CPI is strongly associated with inferior outcomes. Our findings suggest that analysis of ctDNA MRD may enable personalizing the duration of consolidation immunotherapy treatment.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Jun S, Shukla NA, Durm G, et al. Analysis of Circulating Tumor DNA Predicts Outcomes of Short-Course Consolidation Immunotherapy in Unresectable Stage III NSCLC. J Thorac Oncol. 2024. PMID: 38971369. doi:10.1016/j.jtho.2024.06.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。